News >

Brahmer Highlights Immunotherapy Breakthroughs in Metastatic NSCLC

Caroline Seymour
Published: Thursday, Aug 30, 2018

Julie R. Brahmer, MD
Julie R. Brahmer, MD
Immunotherapy advances in the treatment paradigm for patients with metastatic non–small cell lung cancer (NSCLC) could eventually lead to a cure for this disease, said Julie R. Brahmer, MD.

State of the Science Summit™ on Advanced Non–Small Cell Lung Cancer, Brahmer provided an overview of the landscape of metastatic NSCLC, specifically addressing the combination immunotherapy studies with the greatest impact.

OncLive: What do we know about immunotherapy in stage IV disease?

Brahmer: When looking at a patient with metastatic NSCLC, we first look at what type of histology they have–nonsquamous versus squamous–driver mutations they may have, specifically whether or not they have EGFR or ALK or PD-L1 status. Immunotherapy may or may not be an option for most patients with driver mutations, specifically EGFR and ALK. The first-line clinical trials did not include these patients. Right now, therapies such as tyrosine kinase inhibitors (TKIs) are recommended for first-line treatment of these patients.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x